This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Updated from 2:24 p.m. EDT

Shares of OraSure Technologies (OSUR - Get Report) were among the worst-performing health and pharmaceutical stocks Wednesday after the company posted break-even earnings on stronger-than-expected sales but warned that it may not attain full-year profitability.

The diagnostics company reported break-even earnings on sales of $13.2 million. Analysts polled by Thomson First Call had expected it to post a loss of 1 cent a share on sales of $12.8 million. Looking ahead, it forecast full-year sales of $51.5 million to $52.5 million but said that its ability to turn a profit for the year is "now a bit more uncertain." Additional expenses and patent litigation "will make it difficult to achieve full-year profitability in 2004," the company said. Analysts were looking for earnings of 2 cents a share for the year on sales of $51.8 million. Shares of OraSure Technologies traded down $1.42, or 19.3%, to $5.93.

Impax Laboratories (IPXL) fell after it posted weaker-than-expected second-quarter earnings. The pharmaceutical company earned a penny a share on sales of $30.8 million. Analysts were looking for earnings of 3 cents a share on sales of $30.6 million. A year ago it posted a loss of 5 cents a share on sales of $14.1 million. Impax Laboratories shares traded down $1.97, or 14.1%, to $12.

Shares of Reliv International (RELV - Get Report) rose after the company posted in-line second-quarter earnings on better-than-expected sales. The marketer of nutritional supplements posted earnings of 8 cents a share on sales of $23.9 million. Analysts were looking for 8 cents a share on sales of $21.4 million. A year ago it posted earnings of 6 cents a share on sales of $17.8 million. Shares of Reliv International traded up $1.15, or 16.1%, to $8.28.

Nanogen (NGEN) fell after it posted a second-quarter loss on declining sales. The San Diego-based biotechnology diagnostics company posted a loss of 38 cents a share on sales of $1.1 million. A year ago it reported a loss of 32 cents a share on sales of $1.7 million. This year's second quarter included an inventory reserve charge of $1.5 million and a research and development writeoff of $3.8 million. Looking ahead, Nanogen said it does not expect a sales increase for 2004 vs. 2003. Shares of Nanogen traded down 99 cents, or 20.6%, to $3.81.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSUR $6.98 -2.50%
PFE $33.71 2.80%
RELV $0.78 4.00%
AAPL $95.18 1.60%
GOOG $692.33 -0.84%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs